Viremia and antibody response in green monkeys (Chlorocebus aethiops sabaeus) infected with dengue virus type 2: A potential model for vaccine testing

被引:20
作者
Martin, Jorge [1 ]
Hermida, Lisset [1 ]
Castro, Jorge [1 ]
Lazo, Laura [1 ]
Martinez, Rafael [1 ]
Gil, Lazaro [1 ]
Romero, Yaremis [1 ]
Puente, Pedro [1 ]
Zaragoza, Santiago [1 ]
Cosme, Karelia [1 ]
Guzman, Maria G. [2 ]
Cardosa, Jane [3 ]
Guillen, Gerardo [1 ]
机构
[1] Ctr Genet Engn & Biotechnol CIGB, Havana 10600 6, Cuba
[2] Pedro Kour Trop Med Inst IPK, Havana, Cuba
[3] Univ Sarawak, IHCM, Samarahan 94300, Sarawak, Malaysia
关键词
dengue; monkeys; viremia; LIVE-ATTENUATED VACCINE; YELLOW-FEVER VIRUS; RHESUS-MONKEYS; 4; SEROTYPES; IMMUNE-RESPONSES; ENVELOPE PROTEIN; AOTUS-NANCYMAE; DNA VACCINE; RECOMBINANT; PROTECTION;
D O I
10.1111/j.1348-0421.2009.00112.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The increasingly limited availability and high cost of the hitherto most commonly used monkey species in dengue vaccine research has augmented the importance of identifying alternative suitable models for these studies. In this study we examined the capacity of green monkeys (Chlorocebus aethiops sabaeus) to develop dengue viremia, and thus provide a potential model for dengue vaccine testing. Monkeys were inoculated with two different doses of dengue virus type 2. All animals in both groups became viremic after inoculation of the virus. In the lower dose group, mean viremia duration of 5.66 days was detected, whereas in the group that received the 10(6) PFU dose, viremia had a mean duration of only 1.66 days. Antibody titers were similar to those obtained in previous experiments with rhesus and cynomolgus macaques. We conclude that green monkeys develop viremia and antibody responses and therefore provide a potential model for the preclinical evaluation of novel candidates for dengue vaccines.
引用
收藏
页码:216 / 223
页数:8
相关论文
共 55 条
[1]  
ALISON JJ, 2000, J CLIN MICROBIOL, V38, P1827
[2]   Immunization with a recombinant fowlpox virus expressing a hepatitis C virus core-E1 polyprotein variant, protects mice and African green monkeys (Chlorocebus aethiops sabaeus) against challenge with a surrogate vaccinia virus [J].
Alvarez-Lajonchere, Liz ;
Amador-Canizares, Yalena ;
Frias, Roberto ;
Milian, Yoamel ;
Musacchio, Alexis ;
Guerra, Ivis ;
Acosta-Rivero, Nelson ;
Martinez, Gillian ;
Castro, Jorge ;
Puentes, Pedro ;
Cosme, Karelia ;
Duenas-Carrera, Santiago .
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2008, 51 (02) :97-105
[3]   DENGUE-4 VACCINE - NEUROVIRULENCE, VIREMIA AND IMMUNE-RESPONSES IN RHESUS AND CYNOMOLGUS MONKEYS [J].
ANGSUBHAKORN, S ;
YOKSAN, S ;
BHAMARAPRAVATI, N ;
MOE, JB ;
MARCHETTE, NJ ;
PRADERMWONG, A ;
SAHAPHONG, S .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1988, 82 (05) :746-749
[4]  
[Anonymous], 2003, ILAR J, V44, P222
[5]  
Baulu Jean, 2002, Laboratory Primate Newsletter, V41, P4
[6]  
Bente Dennis A, 2006, Drug Discov Today Dis Models, V3, P97, DOI 10.1016/j.ddmod.2006.03.014
[7]   Evaluation of immunity and protective efficacy of a dengue-3 premembrane and envelope DNA vaccine in Aotus nancymae monkeys [J].
Blair, PJ ;
Kochel, TJ ;
Raviprakash, K ;
Guevara, C ;
Salazar, M ;
Wu, SJ ;
Olson, JG ;
Porter, KR .
VACCINE, 2006, 24 (09) :1427-1432
[8]   Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys [J].
Blaney, JE ;
Matro, JM ;
Murphy, BR ;
Whitehead, SS .
JOURNAL OF VIROLOGY, 2005, 79 (09) :5516-5528
[9]   Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells [J].
Blaney, JE ;
Manipon, GG ;
Firestone, CY ;
Johnson, DH ;
Hanson, CT ;
Murphy, BR ;
Whitehead, SS .
VACCINE, 2003, 21 (27-30) :4317-4327
[10]  
Butrapet Siritorn, 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P589